Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-γ and -β:: implications to multiple sclerosis

被引：27

作者：

Galboiz, Y

Shapiro, S

Lahat, N

Miller, A

机构：

[1] Carmed Med Ctr, Dept Neurol, Neuroimmunol Unit, IL-34362 Haifa, Israel

[2] Carmed Med Ctr, Res Immunol Unit, IL-34362 Haifa, Israel

[3] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel

[4] Technion Israel Inst Technol, Fac Med, IL-32000 Haifa, Israel

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2002年 / 131卷 / 1-2期

关键词：

MMP; TIMP; cytokines; multiple sclerosis; autoimmunity;

D O I：

10.1016/S0165-5728(02)00266-7

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Recent findings have implicated the activity of matrix metalloproteinases (MMPs) in the pathogenesis of multiple sclerosis (MS), while in vivo interferon (IFN)-beta treatment was demonstrated to suppress MMPs. In the present study, the effects mediated by IFN-gamma and IFN-beta on the mRNA and protein expression of MMP-2, its physiological activator, MT1-MMP and its endogenous inhibitor, TIMP-2, by monocytes were evaluated in vitro. The results point to the significance of IFNs in modulating MMPs/tissue inhibitors of MMPs (TIMPs) expression, and support the possibility that the therapeutic effects of IFN-beta may be, in part, due to induction of a shift from "pro-" to "anti-proteolytic" pattern of MMPs and TIMPs expression. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

收藏

页码：191 / 200

页数：10

相关论文

共 66 条

[1]

Multiple sclerosis: variations on a theme [J].

Amor, S ;

Baker, D ;

Layward, L ;

McCormack, K ;

vanNoort, JM .

IMMUNOLOGY TODAY, 1997, 18 (08) :368-371

[2]

Interferon beta in multiple sclerosis [J].

Arnason, BGW .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 81 (01) :1-11

[3]

Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation [J].

Baramova, EN ;

Bajou, K ;

Remacle, A ;

LHoir, C ;

Krell, HW ;

Weidle, UH ;

Noel, A ;

Foidart, JM .

FEBS LETTERS, 1997, 405 (02) :157-162

[4]

Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases [J].

Borden, P ;

Heller, RA .

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2) :159-178

[5]

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 [J].

Brooks, PC ;

Stromblad, S ;

Sanders, LC ;

vonSchalscha, TL ;

Aimes, RT ;

StetlerStevenson, WG ;

Quigley, JP ;

Cheresh, DA .

CELL, 1996, 85 (05) :683-693

[6]

The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A - A kinetic study [J].

Butler, GS ;

Butler, MJ ;

Atkinson, SJ ;

Will, H ;

Tamura, T ;

van Westrum, SS ;

Crabbe, T ;

Clements, J ;

d'Ortho, MP ;

Murphy, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (02) :871-880

[7]

Matrix metalloproteinases degrade myelin basic protein [J].

Chandler, S ;

Coates, R ;

Gearing, A ;

Lury, J ;

Wells, G ;

Bone, E .

NEUROSCIENCE LETTERS, 1995, 201 (03) :223-226

[8]

IFN-γ inhibits AP-1 binding activity in human brain-derived cells through a nitric oxide dependent mechanism [J].

Conant, K ;

Ahmed, U ;

Schwartz, JP ;

Major, EO .

JOURNAL OF NEUROIMMUNOLOGY, 1998, 88 (1-2) :39-44

[9]

The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution [J].

Cuzner, ML ;

Gveric, D ;

Strand, C ;

Loughlin, AJ ;

Paemen, L ;

Opdenakker, G ;

Newcombe, J .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (12) :1194-1204

[10]

Deryugina EI, 1998, CANCER RES, V58, P3743

← 1 2 3 4 5 6 7 →